The spectrum of plasma cell neoplasm represents indolent conditions like Monoclonal Gammopathy of Undetermined Significance (MGUS) to more aggressive multiple myeloma and plasma cell leukemia. Non-secretory myeloma comprises less than 01% of this spectrum where serum protein electrophoresis and quantitative immunoglobulins remain essentially normal. We are presenting a case report of this rare variant involving the sternum of an adult male.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Predictive Role of Soluble B-Cell Maturation Antigen in Short-Term Monitoring of Differently Treated Multiple Myeloma Patients: A Prospective Study.
J Clin Lab Anal
January 2025
Hematology Division, Pisa University Hospital, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Background: The management of multiple myeloma is challenging because the disease is incurable and unexpected relapses can threaten a patient's survival. Several assessment systems are currently available, but they often require invasive or costly procedures (e.g.
View Article and Find Full Text PDFSoluble B-cell maturation antigen (sBCMA) is overexpressed on multiple myeloma (MM) cells. We investigated whether sBCMA levels correlated with other myeloma tumor volume indicators and its utility in monitoring oligo-secretory/non-secretory (O-S/Non-S) MM. In 115 patients with newly diagnosed MM, sBCMA was compared with M-protein levels, bone marrow plasma cells (BMPCs), circulating tumor cells (CTCs), and total diffusion volume (tDV; estimated by whole-body diffusion-weighted magnetic resonance imaging) at diagnosis.
View Article and Find Full Text PDFMultiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria.
Leuk Lymphoma
December 2024
Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Article Synopsis
- - Patients with specific types of multiple myeloma face high rates of poor outcomes and need new treatment options; however, strict eligibility criteria for clinical trials limit their access and the generalizability of trial findings.
- - A systematic review of 80 randomized controlled trials from 2006 to 2023 revealed that many exclusion criteria affect patient participation, including age, life expectancy, and various health conditions.
- - Over time, the prevalence of these exclusion criteria has not improved, with some criteria, like those related to neuropathy, actually worsening, creating challenges in developing effective treatments for complex myeloma cases.
Prognostic factors and clinical characteristics of patients with newly diagnosed non-secretory multiple myeloma in the era of new drugs in "real-world" study: Experiences of the Polish Myeloma Group.
Adv Clin Exp Med
August 2024
Plasma Cell Dyscrasias Center, Department of Hematology, Faculty of Medicine, Jagiellonian University Medical College, Cracow, Poland.
Background: Non-secretory multiple myeloma (NSMM) accounts for approx. 2-3% of multiple myeloma (MM) cases. Due to the rare occurrence and ineligibility of patients with NSMM to participate in clinical trials, we have limited data on treatment efficacy and the clinical course in these patients.
View Article and Find Full Text PDFExtended Follow-Up and Analysis of Non-secretory IgG-Type Multiple Myeloma in a Patient With Fibromyalgia: A Case Report.
Cureus
June 2024
Community Medicine Management, Shimane University Faculty of Medicine, Izumo, JPN.
Fibromyalgia (FM) presents a diagnostic challenge due to its complex symptoms and lack of definitive tests. This study discusses a 54-year-old female initially diagnosed with FM, characterized by widespread pain, fatigue, and tender points. Despite treatment, she developed elevated C-reactive protein (CRP) and anemia after two years, leading to further investigations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!